Skip to main content

Correction: Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL TM)

The Original Article was published on 30 June 2022

Correction: AAPS Open 8, 11 (2022)

https://doi.org/10.1186/s41120-022-00058-1

Following publication of the original article (Kemper et al., 2022), the authors identified an error in the author name Dariush Behnam. The family name was incorrectly used throughout the article.

The incorrect author name is: Dariush Benham

The correct author name is: Dariush Behnam

The sentence currently in the Introduction section currently reads:

JOTROLTM is a micellar 10% resveratrol solubilization formulation that is thought to increase the amount of resveratrol and metabolite concentrations in the blood via the lymphatic system (Benham and Hayward 2022).

The sentence should read:

JOTROLTM is a micellar 10% resveratrol solubilization formulation that is thought to increase the amount of resveratrol and metabolite concentrations in the blood via the lymphatic system (Behnam and Hayward 2022).

The Authors’ contributions section currently reads:

DBenham, SB, CW, CHV, and MH were engaged in early preclinical and clinical development and reporting of observations with JOTROL™ and were engaged in the authorship of this manuscript. CK and MH were engaged with specific design and interpretation elements of the PK study and authorship of the manuscript. DBennett was engaged with bioanalytical aspects of the PK study and authorship of the clinical study report and contributed to the editing of this manuscript. The author(s) read and approved the final manuscript.

The Authors’ contributions section should read:

DBehnam, SB, CW, CHV, and MH were engaged in early preclinical and clinical development and reporting of observations with JOTROL™ and were engaged in the authorship of this manuscript. CK and MH were engaged with specific design and interpretation elements of the PK study and authorship of the manuscript. DBennett was engaged with bioanalytical aspects of the PK study and authorship of the clinical study report and contributed to the editing of this manuscript. The author(s) read and approved the final manuscript.

The Competing Interest section currently reads:

CK is a paid consultant of Jupiter Neurosciences (Jupiter).

DBenham is a principle of the company which has licensed technology to Jupiter but has no direct remunerative relationship with Jupiter. Aquanova owns no equity but does have unexecuted stock options.

SB and CW are Jupiter founders and have an equity position in the company.

They are also paid consultants of Jupiter. Both hold unexecuted stock options.

CV is a paid consultant of Jupiter and has unexecuted stock options.

DBennett has no direct financial relationship with Jupiter other than as a paid employee of Syneos Health, the CRO for the PK study.

MH is a founder, employee, and member of the board of directors of Jupiter, has an equity position in Jupiter, is remunerated per an employment contract, and holds unexecuted stock options.

The Competing Interest section should read:

CK is a paid consultant of Jupiter Neurosciences (Jupiter).

DBehnam is a principle of the company which has licensed technology to Jupiter but has no direct remunerative relationship with Jupiter. Aquanova owns no equity but does have unexecuted stock options.

SB and CW are Jupiter founders and have an equity position in the company.

They are also paid consultants of Jupiter. Both hold unexecuted stock options.

CV is a paid consultant of Jupiter and has unexecuted stock options.

DBennett has no direct financial relationship with Jupiter other than as a paid employee of Syneos Health, the CRO for the PK study.

MH is a founder, employee, and member of the board of directors of Jupiter, has an equity position in Jupiter, is remunerated per an employment contract, and holds unexecuted stock options.

The reference current reads:

Benham D, Hayward M (2022) US patent 10,780,056

The reference should read:

Behnam D, Hayward M (2022) US patent 10,780,056

The author group, affected citation, reference and Declarations have been updated above and the original article (Kemper et al., 2022) has been corrected.

Reference

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Marshall Hayward.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kemper, C., Behnam, D., Brothers, S. et al. Correction: Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL TM). AAPS Open 8, 13 (2022). https://doi.org/10.1186/s41120-022-00061-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s41120-022-00061-6